Form 4: Treace Medical Concepts Executive Sean Scanlan Reports Stock Disposals for Tax Obligations

Sean Scanlan, Chief Innovation Officer at Treace Medical Concepts, reports disposing of shares to cover tax obligations related to restricted stock units.

Summary

• On March 8, 2025, Sean Scanlan, Chief Innovation Officer of Treace Medical Concepts, disposed of 401 shares of common stock to satisfy tax obligations.
• The disposal was conducted at a price of $0 per share.
• Following this transaction, Scanlan directly owns 365,477 shares, including 330,829 restricted stock units.
• On March 10, 2025, Scanlan disposed of an additional 1,396 shares of common stock for tax obligations at $0 per share.
• After this second transaction, Scanlan directly owns 364,081 shares, including 325,098 restricted stock units.

Sentiment

Score: 5

Explanation: This is a routine filing related to tax obligations, so it's neutral in sentiment. It doesn't indicate any strategic shift or concern.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment or misalignment of interests between management and shareholders.

Stakeholder Impact

• The disposals are unlikely to have a significant impact on shareholders, as they are related to tax obligations and represent a small percentage of Scanlan's holdings.

Key Dates